Tagged with ALS

Actelion Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness around this rare disease through open communication with health authorities, and the need for formal recognition of orphan drugs by…

Bayer Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently from its R&D pipeline. The affiliate is also focusing on its role as a contributor to Turkish society with R&D,…

hospitals Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years.  How did Medipol come into existence, and where does the hospital stand today? Medipol was opened three years ago, and today the hospital has 500 beds,…

clinical trials The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303 in 2012, with 367 clinical trials performed by local companies. In the same year, Seoul was ranked the number one…

R&D Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses this facility’s role as a role model in the industry, and how the country can improve investment incentives to better…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

Celgene Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the market, how pro-patients and pro-innovation policies need to be supported, how innovative ways need to be found to ensure patient…

hospitals The secretary general of the association representing Turkish private hospitals dicusses the private sector’s role in the Turkish healthcare system, as a subset of hospitals with a particularly high standards and robust medical infrastructure. Could you please begin by explaining the role of OHSAD plays in the Turkish medical community?…

clinical trials The president of the association representing clinical research organisations speaks out about Romania’s attractiveness as a destination country in an era of clinical research globalisation. He further sheds ideas on fostering greater in-country R&D activity and outlines his personal vision for developing the association. How did the association come into…

hospitals Luis Pinillos and Carlos Vallejos both served as Directors of INEN, the Cancer Institute and Minister of Health during President Garcia’s administrations. They discuss the achievements made before, during and after their terms, as well as the exciting new developments being made with the Grupo Auna, as a leading network…

oncology Despite Peru’s sometimes-sluggish development when it comes to healthcare, the progression of cancer prevention and control in recent decades is tremendous. This is particularly important as the number of cancer cases increases by 50,000 annually in Peru. Communicable diseases like infectious diseases, which used to be a predominant cause of death…

R&D “When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he gazes down at the busy, sundrenched streets of Seoul below. “I thought that the global business of Korean pharmaceutical companies…